News

Eli Lilly and Company (NYSE:LLY) is expanding its footprint into the non-opioid pain management market in pursuit of growth ...
The deal prepares for a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from ...
Eli Lilly and Co. announced plans on Tuesday to acquire private biotechnology company San Francisco-based SiteOne ...
Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...
We recently published a list of Jim Cramer Had These 21 Stocks on His Radar. In this article, we are going to take a look at ...
Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...
The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.
Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...
The stock's rise snapped a five-day losing streak.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...
The U.S. imports more pharmaceutical products from Ireland than from any other country -- nearly $50 billion last year. It won't be surprising if the Trump administration especially targets those ...
Unlike the Get Better campaign — which was built throughout last year — Seeking launched with a full body of creative work, ...